A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease
Sponsor: Takeda
Listed as NCT05582993, this PHASE3 trial focuses on Von Willebrand Disease (VWD) and remains actively recruiting participants. Sponsored by Takeda, it has been updated 8 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE3
-
Apr 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2022 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .